Company intelligence / Profile preview

MicroBplex

Atlanta, Georgia, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

MicroBplex has developed a novel class of in vitro diagnostic products aimed at providing early detection of infectious diseases and assessing therapeutic response. Their platform is being evaluated in clinical studies, including diagnostics for early Lyme disease. The company’s technology uses a matrix approach to identify microbial infections such as pneumonia and influenza, with ongoing efforts to commercialize these products.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic deviceIn vitro diagnostic productPlatform technology (diagnostics)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on MicroBplex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroBplex.

Explore the full profile